CE-Ventures (Crescent Enterprises)
Corporate venture capital platform of Crescent Enterprises, investing in early- to late-stage high-growth companies and venture funds globally. Focus on tech-enabled solutions across US, MENA, India, and Southeast Asia with significant biotech exposure.
Location
Sharjah, UAE
Founded
2017
AUM
$500M+
Investment Range
$5M - $50M
Portfolio Companies
4
Focus
generalist
Fund Stages
seed, series-a, series-b, series-c, growth
Investment Thesis
CE-Ventures maintains a versatile, thesis-driven approach investing across consumer, deep-tech, and biotech sectors. They leverage Crescent Enterprises' global network to support portfolio companies across US, MENA, India, and Southeast Asia markets, focusing on companies with transformative potential.
Team
Partners / Managing Directors (Health & Bio Focus)
- Tushar Singhvi - Deputy CEO & Head of CE-Ventures
- Badr Jafar - CEO, Crescent Enterprises
Other Key Team Members
- Investment team with global venture experience
Focus Areas
- Biotechnology
- Deep Tech
- Consumer Technology
- Microbiome
- Gene Editing
- Healthcare Technology
- MENA, India, Southeast Asia Markets
Notable Exits
- Portfolio companies with combined $1B+ raised post-investment
- Active portfolio of 26 tech startups and 9 VC funds
Portfolio Companies (Healthcare/Biotech)
- Freya Biosciences (microbiome-based women's health)
- Exeliom Bio (microbiome-based immunotherapy)
- Prime Medicine (gene editing/prime editing)
- CrossBridge Bio (clinical-stage biopharmaceutical)
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Freya Biosciences | South San Francisco, California, USA | 2019 | therapeuticsbiotech+2 |
| Exeliom Biosciences | Lyon, France | 2016 | biotechmicrobiome+3 |
| Prime Medicine | Cambridge, Massachusetts, USA | 2019 | biotechgene-editing+2 |
| CrossBridge Bio | Dubai, UAE | - | biotechtherapeutics+2 |